The St. Jude Cardiac Defibrillator recall was a significant health crisis that affected hundreds of thousands of patients who depended on implanted heart devices for survival. In October 2016, St. Jude Medical (now Abbott Laboratories) issued a recall of multiple implantable cardioverter-defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) models after discovering a critical battery defect that could cause sudden device failure. Patients like those with Unify, Promote, Fortify, and Quadra Assura devices—among others—faced the frightening possibility that their life-saving devices could stop working without warning. The defect was traced to lithium clusters forming inside the lithium-based batteries used in these devices. These clusters created abnormal electrical connections within the battery, causing short circuits and rapid battery depletion. In some cases, devices lost all power within 24 hours of an FDA alert being issued, leaving patients at critical risk.
What made this recall even more troubling was that St. Jude Medical had allegedly known about the battery defect internally as early as 2011—but did not issue a public recall until 2016, a gap of approximately five years during which patients unknowingly used defective devices. The company paid $27 million in a class action settlement to address the harm caused by these faulty devices, and third-party insurance payers also pursued legal action seeking $9.9 million from St. Jude Medical and Abbott Laboratories. This case, formally known as ASEA/AFSCME Local 52 Health Benefits Trust v. Abbott Laboratories, et al., (No. 1:17-cv-6704), was heard in the U.S. District Court for the Northern District of Illinois, Eastern Division.
Table of Contents
- What Caused the St. Jude Cardiac Defibrillator Defect?
- The Hidden Timeline: Why the Recall Took Five Years
- Health Risks and Patient Impact from Battery Failure
- The Class Action Settlement and Compensation Process
- Regulatory Response and Device Manufacturer Accountability
- Device Replacement and Long-Term Management
- Future Implications for Medical Device Safety
What Caused the St. Jude Cardiac Defibrillator Defect?
The root cause of the recall centered on a manufacturing defect in the lithium-based batteries that powered the implantable devices. Lithium clusters would develop inside the battery casing over time, forming abnormal electrical connections that short-circuited the power system. This wasn’t a gradual degradation that patients might notice and seek help for—it was a sudden failure that could occur with little or no warning. The FDA received reports of battery depletion occurring in rapid timeframes, sometimes within just 24 hours of a device alert being issued, which is an extraordinarily dangerous situation for someone whose heart depends on the device’s constant functionality.
The defect affected numerous device models across St. Jude Medical’s product line, including the Current, Promote, Fortify, Fortify Assura, Quadra Assura, Quadra Assura MP, Unify, Unify Assura, Unify Quadra, Promote Quadra, and Ellipse series. This broad range meant that hundreds of thousands of patients worldwide were potentially at risk. Some patients had their devices implanted years before the recall was issued, meaning they had been unknowingly living with a dangerous defect for years while going about their daily lives.
The Hidden Timeline: Why the Recall Took Five Years
One of the most alarming aspects of this recall was the timeline gap between when St. Jude Medical allegedly discovered the defect and when it was publicly disclosed and acted upon. internal company knowledge of the battery defect reportedly dated back to 2011, but the actual recall announcement didn’t come until October 10, 2016. This five-year delay meant that millions of implanted devices continued circulating in patient bodies while the company was aware of the risk. Patients who received these devices during those years had no way of knowing their hearts were potentially in jeopardy.
This extended delay raises serious questions about corporate responsibility and patient safety priorities. A warning issued in 2011 could have allowed physicians and patients to plan for device replacements, managed the risk more strategically, and potentially prevented adverse health events. Instead, patients discovered the risk only when the FDA and St. Jude Medical finally made the recall public. The company’s decision to delay disclosure—whether for business, regulatory, or other reasons—put patient safety secondary to other considerations, a reality that the legal system attempted to address through the class action settlement.
Health Risks and Patient Impact from Battery Failure
Patients with these defective devices faced immediate and potentially life-threatening risks. Implantable cardioverter-defibrillators and CRT-D devices are designed to detect dangerous heart rhythms and deliver electrical therapy to restore normal heart function. When these devices fail suddenly, patients lose the critical protection they depend on. For someone with an underlying cardiac condition severe enough to require an implanted defibrillator, a device failure can mean the difference between life and death.
The risk wasn’t theoretical or distant—it was urgent and active. Some patients experienced device alerts indicating battery depletion within hours, forcing them to seek emergency medical attention and undergo unscheduled device replacement surgery. Others lived with the stress and anxiety of knowing their device might fail at any moment, unable to engage in normal activities without fear. Patients had to schedule replacement surgeries quickly, deal with the physical and emotional toll of revision procedures, and manage the cost and recovery time associated with having their devices replaced.
The Class Action Settlement and Compensation Process
Abbott Laboratories agreed to pay $27 million to resolve class action claims related to the defective devices. This settlement was structured to compensate patients, and in parallel, third-party insurance payers—including health plans and health insurance companies—pursued their own legal action seeking $9.9 million from St. Jude Medical and Abbott Laboratories for the costs they bore in covering emergency device replacements and related medical care. The insurance payors’ case was significant because it recognized that the defect imposed costs not just on patients, but on the entire healthcare system.
To claim compensation from the settlement, affected patients typically need to provide evidence that they owned or implanted one of the recalled device models during the relevant period. The settlement process usually involves submitting claim forms with device identification information, medical records, and documentation of any related expenses or health impacts. Patients should be aware that there are often deadlines for filing claims—missing these deadlines can result in forfeiture of compensation eligibility. Those with recalled devices from the affected models should review their device documentation, consult with their cardiologist about whether they were impacted, and investigate their eligibility for settlement compensation.
Regulatory Response and Device Manufacturer Accountability
The FDA classified this recall as a Class I recall, the most serious classification indicating that use of the product could cause serious adverse health consequences or death. This high-level classification reflected the severity of the defect and the immediate danger it posed to patients. The FDA’s involvement ensured that the recall was handled through proper regulatory channels and that both physicians and patients received official notification about the defect and recommended actions.
The regulatory response, while necessary, also highlighted a critical gap: how could a major device manufacturer be aware of a serious defect for five years without issuing a recall? The case prompted broader discussions in the medical device industry about disclosure requirements, internal quality control procedures, and manufacturer accountability. For patients, the key limitation is that regulatory action, while important for safety, typically comes after the fact—once the defect is already in thousands or millions of bodies. This is why staying informed about device recalls and maintaining regular follow-up appointments with your cardiologist is essential for safety.
Device Replacement and Long-Term Management
Patients whose devices were identified as defective faced the necessity of replacement surgery. This isn’t a simple procedure—it involves anesthesia, a surgical incision, removal of the malfunctioning device, and implantation of a replacement device. The surgery carries its own risks including infection, bleeding, and anesthesia complications, though these risks are generally small in experienced hands. Recovery typically takes several weeks, during which patients must restrict certain activities and take precautions to protect the surgical site.
For many patients, the psychological toll extended beyond the physical recovery. The knowledge that a device they had trusted to protect their heart had a hidden defect created anxiety and trust issues. Some patients reported difficulty regaining confidence in their replacement devices, even though the newer models had different designs and addressing the lithium cluster problem. Follow-up care became even more critical, with more frequent device checks and closer monitoring to ensure the replacement device was functioning properly.
Future Implications for Medical Device Safety
The St. Jude defibrillator recall served as a watershed moment in discussions about medical device safety and transparency. It highlighted the importance of strong internal quality control programs, prompt disclosure of known defects, and independent oversight of device manufacturers.
In the years following the settlement, regulatory agencies placed greater emphasis on tracking potential device defects and ensuring that manufacturers reported problems quickly rather than delaying disclosure. For patients and families, this case underscores the importance of staying engaged with your medical care, asking questions about your device and its safety record, and attending regular follow-up appointments with your cardiologist. Medical device recalls continue to occur, but increased vigilance and prompt manufacturer reporting have improved the system’s ability to identify and address problems before they cause widespread harm. The settlement, while not erasing the harm to patients who lived with defective devices, provided some measure of justice and accountability.
You Might Also Like
- Stryker Rejuvenate Hip Implant Recall Class Action
- Zimmer NexGen Knee Implant Loosening Class Action
- Zetia Vytorin Cholesterol Antitrust Class Action Settlement
Open Settlements You Can Claim Now
Browse current class action settlements accepting claims — several require no proof of purchase: